ID   FAAA_HUMAN              Reviewed;         419 AA.
AC   P16930; B2R9X1; D3DW95; Q53XA7;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 2.
DT   15-MAR-2017, entry version 173.
DE   RecName: Full=Fumarylacetoacetase;
DE            Short=FAA;
DE            EC=3.7.1.2 {ECO:0000250|UniProtKB:P35505};
DE   AltName: Full=Beta-diketonase;
DE   AltName: Full=Fumarylacetoacetate hydrolase;
GN   Name=FAH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1998338;
RA   Phaneuf D., Labelle Y., Berube D., Arden K., Cavenee W., Gagne R.,
RA   Tanguay R.M.;
RT   "Cloning and expression of the cDNA encoding human fumarylacetoacetate
RT   hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment
RT   of the gene to chromosome 15.";
RL   Am. J. Hum. Genet. 48:525-535(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Small intestine;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-25; 32-47; 83-95 AND 195-211, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V.;
RL   Submitted (JAN-2010) to UniProtKB.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 71-419 (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=2336361; DOI=10.1093/nar/18.7.1887;
RA   Agsteribbe E., van Faassen H., Hartog M.V., Reversma T.,
RA   Taanman J.-W., Pannekoek H., Evers R.F., Welling G.M., Berger R.;
RT   "Nucleotide sequence of cDNA encoding human fumarylacetoacetase.";
RL   Nucleic Acids Res. 18:1887-1887(1990).
RN   [10]
RP   REVIEW ON VARIANTS.
RX   PubMed=9101289;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.3.CO;2-L;
RA   St Louis M., Tanguay R.M.;
RT   "Mutations in the fumarylacetoacetate hydrolase gene causing
RT   hereditary tyrosinemia type I: overview.";
RL   Hum. Mutat. 9:291-299(1997).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-309 AND TYR-395, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   VARIANT TYRSN1 ILE-16.
RX   PubMed=1401056; DOI=10.1172/JCI115979;
RA   Phaneuf D., Lambert M., Laframboise R., Mitchell G., Lettre F.,
RA   Tanguay R.M.;
RT   "Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity
RT   and identification of a causal mutation in a French Canadian
RT   patient.";
RL   J. Clin. Invest. 90:1185-1192(1992).
RN   [15]
RP   VARIANT TYRSN1 ASP-134.
RX   PubMed=8364576; DOI=10.1093/hmg/2.7.941;
RA   Labelle Y., Phaneuf D., Leclerc B., Tanguay R.M.;
RT   "Characterization of the human fumarylacetoacetate hydrolase gene and
RT   identification of a missense mutation abolishing enzymatic activity.";
RL   Hum. Mol. Genet. 2:941-946(1993).
RN   [16]
RP   VARIANT TYRSN1 GLY-166.
RX   PubMed=8318997; DOI=10.1002/humu.1380020205;
RA   Grompe M., Al-Dhalimy M.;
RT   "Mutations of the fumarylacetoacetate hydrolase gene in four patients
RT   with tyrosinemia, type I.";
RL   Hum. Mutat. 2:85-93(1993).
RN   [17]
RP   VARIANT TYRSN1 VAL-233.
RX   PubMed=7942842;
RA   Rootwelt H., Berger R., Gray G., Kelly D.A., Coskun T.,
RA   Kvittingen E.A.;
RT   "Novel splice, missense, and nonsense mutations in the
RT   fumarylacetoacetase gene causing tyrosinemia type 1.";
RL   Am. J. Hum. Genet. 55:653-658(1994).
RN   [18]
RP   INVOLVEMENT IN TYRSN1, AND VARIANT TRP-341.
RX   PubMed=7977370;
RA   Rootwelt H., Brodtkorb E., Kvittingen E.A.;
RT   "Identification of a frequent pseudodeficiency mutation in the
RT   fumarylacetoacetase gene, with implications for diagnosis of
RT   tyrosinemia type I.";
RL   Am. J. Hum. Genet. 55:1122-1127(1994).
RN   [19]
RP   VARIANTS TYRSN1 ASP-134 AND LEU-342.
RX   PubMed=8005583; DOI=10.1007/BF00201558;
RA   Rootwelt H., Chou J., Gahl W.A., Berger R., Coskun T., Brodtkorb E.,
RA   Kvittingen E.A.;
RT   "Two missense mutations causing tyrosinemia type 1 with presence and
RT   absence of immunoreactive fumarylacetoacetase.";
RL   Hum. Genet. 93:615-619(1994).
RN   [20]
RP   VARIANTS TYRSN1 SER-337 AND GLY-381.
RX   PubMed=7757089; DOI=10.1093/hmg/4.2.319;
RA   St Louis M., Poudrier J., Phaneuf D., Leclerc B., Laframboise R.,
RA   Tanguay R.M.;
RT   "Two novel mutations involved in hereditary tyrosinemia type I.";
RL   Hum. Mol. Genet. 4:319-320(1995).
RN   [21]
RP   VARIANT TYRSN1 GLY-234.
RX   PubMed=7550234; DOI=10.1002/humu.1380060113;
RA   Hahn S.H., Krasnewich D., Brantly M., Kvittingen E.A., Gahl W.A.;
RT   "Heterozygosity for an exon 12 splicing mutation and a W234G missense
RT   mutation in an American child with chronic tyrosinemia type 1.";
RL   Hum. Mutat. 6:66-73(1995).
RN   [22]
RP   VARIANTS TYRSN1 ARG-193 AND VAL-369.
RX   PubMed=8557261; DOI=10.1007/BF00218833;
RA   Ploos van Amstel J.K., Bergman A.J.I.W., van Beurden E.A.C.M.,
RA   Roijers J.F.M., Peelen T., van den Berg I.E.T., Poll-The B.T.,
RA   Kvittingen E.A., Berger R.;
RT   "Hereditary tyrosinemia type 1: novel missense, nonsense and splice
RT   consensus mutations in the human fumarylacetoacetate hydrolase gene;
RT   variability of the genotype-phenotype relationship.";
RL   Hum. Genet. 97:51-59(1996).
RN   [23]
RP   VARIANTS TYRSN1 ASP-158; LEU-261; SER-366 DEL AND HIS-405.
RX   PubMed=9633815;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:1<19::AID-HUMU3>3.0.CO;2-3;
RA   Bergman A.J.I.W., van den Berg I.E.T., Brink W., Poll-The B.T.,
RA   Ploos van Amstel J.K., Berger R.;
RT   "Spectrum of mutations in the fumarylacetoacetate hydrolase gene of
RT   tyrosinemia type 1 patients in northwestern Europe and Mediterranean
RT   countries.";
RL   Hum. Mutat. 12:19-26(1998).
RN   [24]
RP   VARIANT TYRSN1 ARG-279.
RX   PubMed=11196105; DOI=10.1023/A:1026756501669;
RA   Kim S.Z., Kupke K.G., Ierardi-Curto L., Holme E., Greter J.,
RA   Tanguay R.M., Poudrier J., D'Astous M., Lettre F., Hahn S.H.,
RA   Levy H.L.;
RT   "Hepatocellular carcinoma despite long-term survival in chronic
RT   tyrosinaemia I.";
RL   J. Inherit. Metab. Dis. 23:791-804(2000).
RN   [25]
RP   VARIANT TYRSN1 ARG-279.
RX   PubMed=11476670; DOI=10.1186/1471-2156-2-9;
RA   Dreumont N., Poudrier J.A., Bergeron A., Levy H.L., Baklouti F.,
RA   Tanguay R.M.;
RT   "A missense mutation (Q279R) in the fumarylacetoacetate hydrolase
RT   gene, responsible for hereditary tyrosinemia, acts as a splicing
RT   mutation.";
RL   BMC Genet. 2:9-9(2001).
RN   [26]
RP   CHARACTERIZATION OF VARIANTS TYRSN1 ILE-16; CYS-62; ASP-134; ARG-193;
RP   VAL-233; GLY-234 AND ARG-279, AND CHARACTERIZATION OF VARIANT TRP-341.
RX   PubMed=11278491; DOI=10.1074/jbc.M009341200;
RA   Bergeron A., D'Astous M., Timm D.E., Tanguay R.M.;
RT   "Structural and functional analysis of missense mutations in
RT   fumarylacetoacetate hydrolase, the gene deficient in hereditary
RT   tyrosinemia type 1.";
RL   J. Biol. Chem. 276:15225-15231(2001).
RN   [27]
RP   VARIANT TYRSN1 THR-35.
RX   PubMed=20003495; DOI=10.1186/1750-1172-4-28;
RA   Cassiman D., Zeevaert R., Holme E., Kvittingen E.A., Jaeken J.;
RT   "A novel mutation causing mild, atypical fumarylacetoacetase
RT   deficiency (Tyrosinemia type I): a case report.";
RL   Orphanet J. Rare Dis. 4:28-28(2009).
RN   [28]
RP   VARIANT TRP-341.
RX   PubMed=27535533; DOI=10.1038/nature19057;
RG   Exome Aggregation Consortium;
RA   Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E.,
RA   Fennell T., O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B.,
RA   Tukiainen T., Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K.,
RA   Zhao F., Zou J., Pierce-Hoffman E., Berghout J., Cooper D.N.,
RA   Deflaux N., DePristo M., Do R., Flannick J., Fromer M., Gauthier L.,
RA   Goldstein J., Gupta N., Howrigan D., Kiezun A., Kurki M.I.,
RA   Moonshine A.L., Natarajan P., Orozco L., Peloso G.M., Poplin R.,
RA   Rivas M.A., Ruano-Rubio V., Rose S.A., Ruderfer D.M., Shakir K.,
RA   Stenson P.D., Stevens C., Thomas B.P., Tiao G., Tusie-Luna M.T.,
RA   Weisburd B., Won H.H., Yu D., Altshuler D.M., Ardissino D.,
RA   Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C.,
RA   Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S.,
RA   Laakso M., McCarroll S., McCarthy M.I., McGovern D., McPherson R.,
RA   Neale B.M., Palotie A., Purcell S.M., Saleheen D., Scharf J.M.,
RA   Sklar P., Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C.,
RA   Wilson J.G., Daly M.J., MacArthur D.G.;
RT   "Analysis of protein-coding genetic variation in 60,706 humans.";
RL   Nature 536:285-291(2016).
CC   -!- CATALYTIC ACTIVITY: 4-fumarylacetoacetate + H(2)O = acetoacetate +
CC       fumarate. {ECO:0000250|UniProtKB:P35505}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000250|UniProtKB:P35505};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P35505};
CC   -!- PATHWAY: Amino-acid degradation; L-phenylalanine degradation;
CC       acetoacetate and fumarate from L-phenylalanine: step 6/6.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250|UniProtKB:P35505}.
CC   -!- INTERACTION:
CC       Q6UY14-3:ADAMTSL4; NbExp=3; IntAct=EBI-4397076, EBI-10173507;
CC       P60410:KRTAP10-8; NbExp=3; IntAct=EBI-4397076, EBI-10171774;
CC       P26371:KRTAP5-9; NbExp=3; IntAct=EBI-4397076, EBI-3958099;
CC       Q53GC0:SERTAD1; NbExp=3; IntAct=EBI-4397076, EBI-2826300;
CC       P15884:TCF4; NbExp=3; IntAct=EBI-4397076, EBI-533224;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P16930-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P16930-2; Sequence=VSP_055491;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Mainly expressed in liver and kidney. Lower
CC       levels are also detected in many other tissues.
CC   -!- DISEASE: Tyrosinemia 1 (TYRSN1) [MIM:276700]: An inborn error of
CC       metabolism characterized by elevations of tyrosine in the blood
CC       and urine, and hepatorenal manifestations. Typical features
CC       include hepatic necrosis, renal tubular injury, episodic weakness,
CC       self-mutilation, and seizures. Renal tubular dysfunction is
CC       associated with phosphate loss and hypophosphataemic rickets.
CC       Progressive liver disease can lead to the development of
CC       hepatocellular carcinoma. Dietary treatment with restriction of
CC       tyrosine and phenylalanine alleviates the rickets, but liver
CC       transplantation has so far been the only definite treatment.
CC       {ECO:0000269|PubMed:11196105, ECO:0000269|PubMed:11278491,
CC       ECO:0000269|PubMed:11476670, ECO:0000269|PubMed:1401056,
CC       ECO:0000269|PubMed:20003495, ECO:0000269|PubMed:7550234,
CC       ECO:0000269|PubMed:7757089, ECO:0000269|PubMed:7942842,
CC       ECO:0000269|PubMed:7977370, ECO:0000269|PubMed:8005583,
CC       ECO:0000269|PubMed:8318997, ECO:0000269|PubMed:8364576,
CC       ECO:0000269|PubMed:8557261, ECO:0000269|PubMed:9633815}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the FAH family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M55150; AAA52422.1; -; mRNA.
DR   EMBL; BT007160; AAP35824.1; -; mRNA.
DR   EMBL; AK313951; BAG36668.1; -; mRNA.
DR   EMBL; BX537608; CAD97795.1; -; mRNA.
DR   EMBL; AC087761; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471136; EAW99120.1; -; Genomic_DNA.
DR   EMBL; CH471136; EAW99121.1; -; Genomic_DNA.
DR   EMBL; BC002527; AAH02527.1; -; mRNA.
DR   EMBL; X51728; CAA36016.1; -; mRNA.
DR   CCDS; CCDS10314.1; -. [P16930-1]
DR   PIR; A37926; A37926.
DR   RefSeq; NP_000128.1; NM_000137.2. [P16930-1]
DR   UniGene; Hs.73875; -.
DR   ProteinModelPortal; P16930; -.
DR   SMR; P16930; -.
DR   BioGrid; 108479; 11.
DR   IntAct; P16930; 6.
DR   STRING; 9606.ENSP00000261755; -.
DR   DrugBank; DB01832; 4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid.
DR   DrugBank; DB01762; Acetoacetic Acid.
DR   DrugBank; DB01677; Fumarate.
DR   iPTMnet; P16930; -.
DR   PhosphoSitePlus; P16930; -.
DR   SwissPalm; P16930; -.
DR   BioMuta; FAH; -.
DR   DMDM; 119778; -.
DR   OGP; P16930; -.
DR   REPRODUCTION-2DPAGE; IPI00031708; -.
DR   EPD; P16930; -.
DR   MaxQB; P16930; -.
DR   PaxDb; P16930; -.
DR   PeptideAtlas; P16930; -.
DR   PRIDE; P16930; -.
DR   Ensembl; ENST00000261755; ENSP00000261755; ENSG00000103876. [P16930-1]
DR   Ensembl; ENST00000407106; ENSP00000385080; ENSG00000103876. [P16930-1]
DR   Ensembl; ENST00000539156; ENSP00000454271; ENSG00000103876. [P16930-2]
DR   Ensembl; ENST00000561421; ENSP00000453347; ENSG00000103876. [P16930-1]
DR   GeneID; 2184; -.
DR   KEGG; hsa:2184; -.
DR   UCSC; uc002bfm.3; human. [P16930-1]
DR   CTD; 2184; -.
DR   DisGeNET; 2184; -.
DR   GeneCards; FAH; -.
DR   HGNC; HGNC:3579; FAH.
DR   HPA; HPA041370; -.
DR   HPA; HPA044093; -.
DR   MalaCards; FAH; -.
DR   MIM; 276700; phenotype.
DR   MIM; 613871; gene.
DR   neXtProt; NX_P16930; -.
DR   OpenTargets; ENSG00000103876; -.
DR   Orphanet; 882; Tyrosinemia type 1.
DR   PharmGKB; PA27977; -.
DR   eggNOG; KOG2843; Eukaryota.
DR   eggNOG; COG0179; LUCA.
DR   GeneTree; ENSGT00390000008646; -.
DR   HOGENOM; HOG000256845; -.
DR   HOVERGEN; HBG001919; -.
DR   InParanoid; P16930; -.
DR   KO; K01555; -.
DR   OMA; SKSNFKH; -.
DR   OrthoDB; EOG091G00CM; -.
DR   PhylomeDB; P16930; -.
DR   TreeFam; TF315211; -.
DR   BioCyc; MetaCyc:HS02536-MONOMER; -.
DR   Reactome; R-HSA-71182; Phenylalanine and tyrosine catabolism.
DR   UniPathway; UPA00139; UER00341.
DR   ChiTaRS; FAH; human.
DR   GeneWiki; Fumarylacetoacetate_hydrolase; -.
DR   GenomeRNAi; 2184; -.
DR   PRO; PR:P16930; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000103876; -.
DR   CleanEx; HS_FAH; -.
DR   ExpressionAtlas; P16930; baseline and differential.
DR   Genevisible; P16930; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0004334; F:fumarylacetoacetase activity; EXP:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006527; P:arginine catabolic process; IEA:Ensembl.
DR   GO; GO:0006559; P:L-phenylalanine catabolic process; TAS:Reactome.
DR   GO; GO:0006572; P:tyrosine catabolic process; TAS:ProtInc.
DR   Gene3D; 2.30.30.230; -; 1.
DR   Gene3D; 3.90.850.10; -; 1.
DR   InterPro; IPR005959; Fumarylacetoacetase.
DR   InterPro; IPR011234; Fumarylacetoacetase_C-rel.
DR   InterPro; IPR015377; Fumarylacetoacetase_N.
DR   PANTHER; PTHR43069; PTHR43069; 1.
DR   Pfam; PF01557; FAA_hydrolase; 1.
DR   Pfam; PF09298; FAA_hydrolase_N; 1.
DR   SUPFAM; SSF56529; SSF56529; 1.
DR   SUPFAM; SSF63433; SSF63433; 1.
DR   TIGRFAMs; TIGR01266; fum_ac_acetase; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Calcium; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Hydrolase; Magnesium;
KW   Metal-binding; Phenylalanine catabolism; Phosphoprotein;
KW   Reference proteome; Tyrosine catabolism.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.8}.
FT   CHAIN         2    419       Fumarylacetoacetase.
FT                                /FTId=PRO_0000156825.
FT   ACT_SITE    133    133       Proton acceptor. {ECO:0000305}.
FT   METAL       126    126       Calcium. {ECO:0000250|UniProtKB:P35505}.
FT   METAL       199    199       Calcium. {ECO:0000250|UniProtKB:P35505}.
FT   METAL       201    201       Calcium. {ECO:0000250|UniProtKB:P35505}.
FT   METAL       233    233       Calcium. {ECO:0000250|UniProtKB:P35505}.
FT   METAL       233    233       Magnesium.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   METAL       253    253       Magnesium.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   METAL       257    257       Magnesium.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   BINDING     128    128       Substrate.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   BINDING     142    142       Substrate.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   BINDING     240    240       Substrate.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   BINDING     244    244       Substrate.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   BINDING     350    350       Substrate.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.8}.
FT   MOD_RES      92     92       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35505}.
FT   MOD_RES     309    309       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     395    395       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1     70       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_055491.
FT   VARIANT      16     16       N -> I (in TYRSN1; loss of activity;
FT                                dbSNP:rs121965073).
FT                                {ECO:0000269|PubMed:11278491,
FT                                ECO:0000269|PubMed:1401056}.
FT                                /FTId=VAR_005205.
FT   VARIANT      35     35       A -> T (in TYRSN1; atypical mild
FT                                phenotype).
FT                                {ECO:0000269|PubMed:20003495}.
FT                                /FTId=VAR_065454.
FT   VARIANT      62     62       F -> C (in TYRSN1; loss of activity).
FT                                {ECO:0000269|PubMed:11278491}.
FT                                /FTId=VAR_005206.
FT   VARIANT      64     64       Q -> H (in TYRSN1; dbSNP:rs80338894).
FT                                /FTId=VAR_005207.
FT   VARIANT     134    134       A -> D (in TYRSN1; loss of activity;
FT                                dbSNP:rs121965074).
FT                                {ECO:0000269|PubMed:11278491,
FT                                ECO:0000269|PubMed:8005583,
FT                                ECO:0000269|PubMed:8364576}.
FT                                /FTId=VAR_005208.
FT   VARIANT     158    158       G -> D (in TYRSN1).
FT                                {ECO:0000269|PubMed:9633815}.
FT                                /FTId=VAR_005209.
FT   VARIANT     166    166       V -> G (in TYRSN1; dbSNP:rs778387055).
FT                                {ECO:0000269|PubMed:8318997}.
FT                                /FTId=VAR_005210.
FT   VARIANT     193    193       C -> R (in TYRSN1; loss of activity).
FT                                {ECO:0000269|PubMed:11278491,
FT                                ECO:0000269|PubMed:8557261}.
FT                                /FTId=VAR_005211.
FT   VARIANT     207    207       G -> D (in TYRSN1; dbSNP:rs754196530).
FT                                /FTId=VAR_005212.
FT   VARIANT     233    233       D -> V (in TYRSN1; loss of activity;
FT                                dbSNP:rs80338897).
FT                                {ECO:0000269|PubMed:11278491,
FT                                ECO:0000269|PubMed:7942842}.
FT                                /FTId=VAR_005213.
FT   VARIANT     234    234       W -> G (in TYRSN1; loss of activity).
FT                                {ECO:0000269|PubMed:11278491,
FT                                ECO:0000269|PubMed:7550234}.
FT                                /FTId=VAR_005214.
FT   VARIANT     249    249       P -> T (in TYRSN1).
FT                                /FTId=VAR_005215.
FT   VARIANT     261    261       P -> L (in TYRSN1; dbSNP:rs80338898).
FT                                {ECO:0000269|PubMed:9633815}.
FT                                /FTId=VAR_005216.
FT   VARIANT     279    279       Q -> R (in TYRSN1; may affect splicing
FT                                resulting in skipping of exon 8 alone or
FT                                together with exon 9; lower activity as
FT                                compared to wild type;
FT                                dbSNP:rs121965078).
FT                                {ECO:0000269|PubMed:11196105,
FT                                ECO:0000269|PubMed:11278491,
FT                                ECO:0000269|PubMed:11476670}.
FT                                /FTId=VAR_065455.
FT   VARIANT     294    294       T -> P (in TYRSN1; dbSNP:rs370634385).
FT                                /FTId=VAR_005217.
FT   VARIANT     337    337       G -> S (in TYRSN1; dbSNP:rs80338900).
FT                                {ECO:0000269|PubMed:7757089}.
FT                                /FTId=VAR_005218.
FT   VARIANT     341    341       R -> W (functional polymorphism; does not
FT                                cause a clinically relevant phenotype;
FT                                results in lower enzyme activity;
FT                                dbSNP:rs11555096).
FT                                {ECO:0000269|PubMed:11278491,
FT                                ECO:0000269|PubMed:27535533,
FT                                ECO:0000269|PubMed:7977370}.
FT                                /FTId=VAR_005219.
FT   VARIANT     342    342       P -> L (in TYRSN1; loss of activity;
FT                                dbSNP:rs779040832).
FT                                {ECO:0000269|PubMed:8005583}.
FT                                /FTId=VAR_005220.
FT   VARIANT     366    366       Missing (in TYRSN1).
FT                                {ECO:0000269|PubMed:9633815}.
FT                                /FTId=VAR_005221.
FT   VARIANT     369    369       G -> V (in TYRSN1).
FT                                {ECO:0000269|PubMed:8557261}.
FT                                /FTId=VAR_005222.
FT   VARIANT     381    381       R -> G (in TYRSN1; loss of activity;
FT                                dbSNP:rs121965077).
FT                                {ECO:0000269|PubMed:7757089}.
FT                                /FTId=VAR_005223.
FT   VARIANT     405    405       F -> H (in TYRSN1; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:9633815}.
FT                                /FTId=VAR_005224.
SQ   SEQUENCE   419 AA;  46374 MW;  12EA8D8074C55BB2 CRC64;
     MSFIPVAEDS DFPIHNLPYG VFSTRGDPRP RIGVAIGDQI LDLSIIKHLF TGPVLSKHQD
     VFNQPTLNSF MGLGQAAWKE ARVFLQNLLS VSQARLRDDT ELRKCAFISQ ASATMHLPAT
     IGDYTDFYSS RQHATNVGIM FRDKENALMP NWLHLPVGYH GRASSVVVSG TPIRRPMGQM
     KPDDSKPPVY GACKLLDMEL EMAFFVGPGN RLGEPIPISK AHEHIFGMVL MNDWSARDIQ
     KWEYVPLGPF LGKSFGTTVS PWVVPMDALM PFAVPNPKQD PRPLPYLCHD EPYTFDINLS
     VNLKGEGMSQ AATICKSNFK YMYWTMLQQL THHSVNGCNL RPGDLLASGT ISGPEPENFG
     SMLELSWKGT KPIDLGNGQT RKFLLDGDEV IITGYCQGDG YRIGFGQCAG KVLPALLPS
//
